---
title: "Biogen plans to acquire the remaining shares of Sage at a 30% premium"
description: "American pharmaceutical company Biogen announced on Friday that it will acquire the outstanding shares of Sage Therapeutics at a price of $7.22 per share, driving Sage's stock price up 34% in after-ho"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/224645533.md"
published_at: "2025-01-11T06:01:04.000Z"
---

# Biogen plans to acquire the remaining shares of Sage at a 30% premium

> American pharmaceutical company Biogen announced on Friday that it will acquire the outstanding shares of Sage Therapeutics at a price of $7.22 per share, driving Sage's stock price up 34% in after-hours trading. Regulatory filings show that Biogen owns 10.2% of Sage Therapeutics. This offer represents a 30% premium over Sage Therapeutics' closing price on Friday, valuing Sage at $441.7 million. Due to concerns about cost, efficacy, and side effects, Biogen's Alzheimer's drug Leqembi has been slowly recovering in sales in the U.S. Sage's stock price plummeted 75% in 2024. After multiple trial failures, the company abandoned the development of the drug dalzanemdor. Last November, Sage stated that it would focus on the postpartum depression drug Zurzuvae developed in collaboration with Biogen. In July of last year, Sage also abandoned another neurology drug developed in partnership with Biogen

According to the Zhitong Finance APP, American pharmaceutical company Biogen (BIIB.US) announced on Friday that it will acquire the outstanding shares of Sage Therapeutics (SAGE.US) at a price of $7.22 per share, driving the latter's stock price up 34% in after-hours trading.

Regulatory filings show that Biogen owns 10.2% of Sage Therapeutics. This offer represents a 30% premium over Sage Therapeutics' closing price on Friday, valuing Sage at $441.7 million.

Due to concerns about cost, efficacy, and side effects, Biogen's Alzheimer's drug Leqembi has been slowly recovering in sales in the U.S.

Sage's stock price plummeted 75% in 2024. After multiple trial failures, the company abandoned the development of the drug dalzanemdor. Last November, Sage stated that it would focus on the postpartum depression drug Zurzuvae, developed in collaboration with Biogen.

In July of last year, Sage also abandoned the development of another neurological disease drug in collaboration with Biogen

### Related Stocks

- [BIIB.US - Biogen](https://longbridge.com/en/quote/BIIB.US.md)
- [SAGE.US - Sage Therap](https://longbridge.com/en/quote/SAGE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Key facts: Biogen's LEQEMBI gets Priority Review in China; Wedbush raises price target | Biogen and Eisai's LEQEMBI (lecanemab) subcutaneous formulation received Priority Review from China's NMPA, speeding up  | [Link](https://longbridge.com/en/news/275506245.md) |
| Biogen Spotlights Lupus Pipeline at Piper Sandler Symposium: Litifilimab, Dapirolizumab in Focus | Biogen (NASDAQ:BIIB) presented its immunology and neurology development priorities at the Piper Sandler symposium, focus | [Link](https://longbridge.com/en/news/275926142.md) |
| AB Inbev CFO Fernando Tennenbaum: 2026 will hopefully be a more normal year on costs, we see further opportunities to expand margin | AB Inbev CFO Fernando Tennenbaum: 2026 will hopefully be a more normal year on costs, we see further opportunities to ex | [Link](https://longbridge.com/en/news/275819045.md) |
| Atria Investments Inc Has $13.65 Million Holdings in PepsiCo, Inc. $PEP | Atria Investments Inc reduced its stake in PepsiCo, Inc. (NASDAQ: PEP) by 9.3% in Q3, holding 97,185 shares valued at ap | [Link](https://longbridge.com/en/news/275870124.md) |
| Nudge the Ones You Love To Get Checked | Aflac CEO Dan Amos emphasizes the importance of prioritizing health, especially cancer screenings, in a heartfelt messag | [Link](https://longbridge.com/en/news/275791859.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
